Diabetic Macular Edema - Pipeline Insight, 2022
Description
Diabetic Macular Edema - Pipeline Insight, 2022
DelveInsight’s, “Diabetic macular edema – Pipeline Insight, 2022,” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in Diabetic macular edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic macular edema: Overview
Diabetic Macular Edema (DME) is an eye condition which can occur in people living with diabetes – both type 1 and type 2. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, fluid can leak into the center of the macula, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called DME. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. Vision changes due to DME are: Blurred vision, Double vision, and Sudden increase in eye floaters. A detailed history including the approximate date of onset of diabetes, the use of insulin vs. oral antihyperglycemic agents, and the quality of metabolic control (e.g., HbA1c level) should be elicited. Maintaining good blood sugar, blood pressure, and cholesterol control helps prevent DME. Receiving a comprehensive dilated eye exam at least once a year, or more often as directed by the eye doctor. Laser light is used to close and destroy leaking blood vessels. This form of laser therapy does not typically cause pain. The treatment may leave permanent blind spots in a person’s vision. Anti-vascular endothelial growth factor (anti-VEGF) drugs block the development of new blood vessels and limit the leakage from the abnormal blood vessels in the eye.
""Diabetic macular edema - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic macular edema pipeline landscape is provided which includes the disease overview and Diabetic macular edema treatment guidelines. The assessment part of the report embraces, in depth Diabetic macular edema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic macular edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic macular edema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic macular edema Emerging Drugs
Further product details are provided in the report……..
Diabetic macular edema: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic macular edema drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic macular edema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic macular edema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic macular edema drugs.
Diabetic macular edema Report Insights
Current Treatment Scenario and Emerging Therapies:
•Ascentage Pharma
•Rezolute
•Ocuphire Pharma
•Oxurion
•MingSight Pharmaceuticals
•Adverum Biotechnologies
Key Products
•MYL-1701P
•KSI-301
•CT-P42
•OPT 302
•UBX 1325
•RZ402
•APX3330
•THR-687
•MS-553
•ADVM-022
DelveInsight’s, “Diabetic macular edema – Pipeline Insight, 2022,” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in Diabetic macular edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diabetic macular edema: Overview
Diabetic Macular Edema (DME) is an eye condition which can occur in people living with diabetes – both type 1 and type 2. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, fluid can leak into the center of the macula, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called DME. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. Vision changes due to DME are: Blurred vision, Double vision, and Sudden increase in eye floaters. A detailed history including the approximate date of onset of diabetes, the use of insulin vs. oral antihyperglycemic agents, and the quality of metabolic control (e.g., HbA1c level) should be elicited. Maintaining good blood sugar, blood pressure, and cholesterol control helps prevent DME. Receiving a comprehensive dilated eye exam at least once a year, or more often as directed by the eye doctor. Laser light is used to close and destroy leaking blood vessels. This form of laser therapy does not typically cause pain. The treatment may leave permanent blind spots in a person’s vision. Anti-vascular endothelial growth factor (anti-VEGF) drugs block the development of new blood vessels and limit the leakage from the abnormal blood vessels in the eye.
""Diabetic macular edema - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic macular edema pipeline landscape is provided which includes the disease overview and Diabetic macular edema treatment guidelines. The assessment part of the report embraces, in depth Diabetic macular edema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic macular edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic macular edema R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic macular edema.
This segment of the Diabetic macular edema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic macular edema Emerging Drugs
- MYL-1701P: Mylan Pharmaceuticals
- KSI-301: Kodiak sciences
- CT-P42: Celltrion
Further product details are provided in the report……..
Diabetic macular edema: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic macular edema drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic macular edema
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Diabetic macular edema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic macular edema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic macular edema drugs.
Diabetic macular edema Report Insights
- Diabetic macular edema Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic macular edema drugs?
- How many Diabetic macular edema drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic macular edema?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic macular edema therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic macular edema and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mylan Pharmaceuticals
- Kodiak sciences
- Celltrion
- Exonate
- Opthea
- AsclepiX Therapeutics
•Ascentage Pharma
•Rezolute
•Ocuphire Pharma
•Oxurion
•MingSight Pharmaceuticals
•Adverum Biotechnologies
Key Products
•MYL-1701P
•KSI-301
•CT-P42
•OPT 302
- AXT-107
•UBX 1325
•RZ402
•APX3330
•THR-687
•MS-553
•ADVM-022
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Diabetic macular edema: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- Comparative Analysis
- MYL-1701P: Mylan Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetic macular edema Key Companies
- Diabetic macular edema Key Products
- Diabetic macular edema- Unmet Needs
- Diabetic macular edema- Market Drivers and Barriers
- Diabetic macular edema- Future Perspectives and Conclusion
- Diabetic macular edema Analyst Views
- Diabetic macular edema Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
